<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00958386</url>
  </required_header>
  <id_info>
    <org_study_id>TTD-08-06</org_study_id>
    <nct_id>NCT00958386</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA)</brief_title>
  <acronym>SPECTRA</acronym>
  <official_title>Open, Multicenter Phase II Study to Evaluate the Efficacy and Safety of the Combination of Panitumumab With Irinotecan in Patients With Wild-Type KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of the combination of&#xD;
      Panitumumab with Irinotecan in patients with Wild-Type KRAS metastatic colorectal cancer&#xD;
      refractory to irinotecan based chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>2009-2012</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>2009-2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>2009-2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to progression</measure>
    <time_frame>2009-2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to response</measure>
    <time_frame>2009-2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to treatment failure</measure>
    <time_frame>2009-2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of stable disease</measure>
    <time_frame>2009-2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2009-2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2009-2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile</measure>
    <time_frame>2009-2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of molecular predictive markers</measure>
    <time_frame>2009-2012</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panitumumab+irinotecan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab+irinotecan</intervention_name>
    <description>Panitumumab will be administered as a 60 minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. A cycle of Panitumumab is defined as 14 days.&#xD;
Irinotecan chemotherapy (180 mg/m2 in 90 min on day 1 of each cycle) will be administered after the administration of Panitumumab.&#xD;
Each treatment cycle will have a duration of 14 days.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Competent to comprehend, sign, and date an IEC-approved informed consent form.&#xD;
&#xD;
          -  Men or women 18 years of age or older at the time the written informed consent is&#xD;
             obtained.&#xD;
&#xD;
          -  Histologically confirmed metastatic adenocarcinoma of the colon or rectum&#xD;
&#xD;
          -  Wild-Type KRAS (No mutation) by allelic discrimination on tumor DNA.&#xD;
&#xD;
          -  Karnofsky performance status ≥ 70% at the time of enrolment in the study.&#xD;
&#xD;
          -  Within seven days prior to initiating study treatment:&#xD;
&#xD;
               -  Adequate bone marrow function: neutrophils ≥ 1.5x109/ L; platelets ≥ 100x109/L;&#xD;
                  hemoglobin ≥ 9g/dL.&#xD;
&#xD;
               -  Hepatic functions as follows: total bilirubin count ≤ 1.5 x ULN; ALAT and ASAT ≤&#xD;
                  2.5 x ULN (≤5 x ULN in case of liver metastasis).&#xD;
&#xD;
               -  Renal function: serum creatinine ≤1.5 ULN&#xD;
&#xD;
               -  Metabolic functions: magnesium ≥ lower limit of normal (LLN), calcium ≥ lower&#xD;
                  limit of normal (LLN)&#xD;
&#xD;
          -  Life expectancy ≥ 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior malignant tumor in the last 5 years, except a history of basal cell carcinoma of&#xD;
             the skin or pre-invasive cervical cancer.&#xD;
&#xD;
          -  Unresolved toxicities from prior systemic therapy that, in the opinion of the&#xD;
             investigator, does not qualify the patient for inclusion.&#xD;
&#xD;
          -  Documented or suspected central nervous system metastases.&#xD;
&#xD;
          -  Hormonal therapy, immunotherapy or experimental or approved proteins/antibodies (eg,&#xD;
             Bevacizumab) ≤ 30 days before inclusion.&#xD;
&#xD;
          -  Significant cardiovascular disease including unstable angina or myocardial infarction&#xD;
             within 12 months before initiating study treatment or a history of ventricular&#xD;
             arrhythmia.&#xD;
&#xD;
          -  Prior anti-EGFr antibody therapy (eg, Cetuximab) or treatment small molecule EGFr&#xD;
             tyrosine kinase inhibitors (eg, Erlotinib) or EGFR signal transduction inhibitors.&#xD;
             Subjects who discontinue their first dose of anti-EGFR therapy (Cetuximab) because of&#xD;
             an infusion reaction may participate in this clinical trial.&#xD;
&#xD;
          -  Paraffin-embedded tissue or unstained tumor slides from primary or metastatic tumor&#xD;
             not available (blocks available for Translational research).&#xD;
&#xD;
          -  History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial&#xD;
             pneumonitis or pulmonary fibrosis on baseline chest CT scan.&#xD;
&#xD;
          -  Treatment for systemic infection within 14 days before initiating study treatment.&#xD;
&#xD;
          -  Acute or sub-acute intestinal occlusion and /or active inflammatory bowel disease or&#xD;
             other bowel disease causing chronic diarrhoea (defined as &gt; 4 loose stools per day).&#xD;
&#xD;
          -  History of Gilbert's syndrome or dihydropyrimidine deficiency.&#xD;
&#xD;
          -  History of any medical condition that may increase the risks associated with study&#xD;
             participation or may interfere with the interpretation of the study results.&#xD;
&#xD;
          -  Known positive test for human immunodeficiency virus infection, hepatitis C virus, and&#xD;
             chronic active hepatitis B infection.&#xD;
&#xD;
          -  Subject allergic to the ingredients of the study medication or to Staphylococcus&#xD;
             protein A.&#xD;
&#xD;
          -  Any co-morbid disease that would increase risk of toxicity.&#xD;
&#xD;
          -  Any kind of disorder that compromises the ability of the subject to give written&#xD;
             informed consent and/or comply with the study procedures.&#xD;
&#xD;
          -  Any investigational agent within 30 days before initiation of the treatment.&#xD;
&#xD;
          -  Subject who is pregnant or breast feeding.&#xD;
&#xD;
          -  Surgery (excluding diagnostic biopsy or central venous catheter placement) and/or&#xD;
             radiotherapy within 28 days prior to initiation of study treatment.&#xD;
&#xD;
          -  Woman or man of childbearing potential not consenting to use adequate contraceptive&#xD;
             precautions i.e. double barrier contraceptive methods (e.g. diaphragm plus condom), or&#xD;
             abstinence during the course of the study and for 6 months after the last study drug&#xD;
             administration for women, and 1 month for men.&#xD;
&#xD;
          -  Subject unwilling or unable to comply with study requirements.&#xD;
&#xD;
          -  Psychological, familial, sociological, or geographical condition potentially hampering&#xD;
             compliance with the study protocol and follow-up schedule; those conditions should be&#xD;
             discussed with the patient before registration in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josep Tabernero, MD, phD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Vall de Hebrón. Barcelona. Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enrique Aranda, MD; phD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Reina Sofía. Cordoba. Madrid</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spanish Cooperative Group for Gastrointestinal Tumour Therapy</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>August 12, 2009</study_first_submitted>
  <study_first_submitted_qc>August 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2009</study_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>Panitumumab</keyword>
  <keyword>irinotecan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

